Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253702 | 0.93 | SYK (0.39) | EGLN2GSK3BABL1IRAK4JAK1 | |
| SCHEMBL251083 | 0.90 | CSNK1D (0.37) | GSK3B | |
| SCHEMBL250931 | 0.90 | EGLN2 (0.42) | EGLN2ABL1TBK1 | |
| SCHEMBL251899 | 0.90 | ABL1 (0.36) | EGLN2ABL1TBK1 | |
| SCHEMBL252762 | 0.89 | JAK1 (0.39) | GSK3AGSK3BABL1KDM4EJAK1 | |
| SCHEMBL251824 | 0.88 | BRD4 (0.34) | GSK3BABL1KITJAK1 | |
| SCHEMBL252741 | 0.87 | GSK3B (0.45) | GSK3BABL1 | |
| SCHEMBL253289 | 0.86 | MAPK14 (0.40) | GSK3AGSK3B | |
| SCHEMBL252389 | 0.86 | DYRK1A (0.41) | GSK3BABL1KDM4EKITJAK1 | |
| SCHEMBL252772 | 0.85 | GRK5 (0.38) | GSK3BABL1KDM4EJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588107-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | Takeda Pharmaceutical Company Limited (JP) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003338-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-05 | — | — | WO | disclosed |